Efficacy and Safety of Topical Vitamin D Analogue in Treatment of Female Pattern Hair Loss
NCT ID: NCT06333600
Last Updated: 2024-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
45 participants
INTERVENTIONAL
2023-05-20
2024-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intralesional Vitamin D in Alopecia Areata
NCT04660786
Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
NCT07012486
Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia
NCT07273799
Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata
NCT04003376
Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia
NCT07056933
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study design: A prospective, randomized, controlled clinical study. Study population: The study will include 45 females aged 15-70 years attending Dermatology outpatient clinic at Sohag University Hospital with a complaint of chronic diffuse hair loss diagnosed clinically and will be confirmed by trichoscope as FPHL and with serum vitamin D deficiency.
Exclusion criteria will include:
* Patients with other hair loss disorders as telogen effluvium, anagen effluvium, alopecia areata, cicatricial alopecia and trichotillomania.
* Oral or parentral vitamin D supplementation for the last 3 months
* Treatment with topical vitamin D analogs in the past month
* Patients who received hair tonics or any specific hair therapy over the last 3 months prior to enrollement in the study.
* Patients with diabetes mellitus, renal disease, thyroid and parathyroid abnormalities, or autoimmune diseases.
* Patients who are pregnant, lactating or on contraceptive pills.
All patients in this study will be subjected to:
1. Complete history including:
* Personal history: age, occupation, residence, marital status, special habits of medical importance
* Menstrual and obstetric history
* Average time spent outdoor (per hour)
* Diatery habits
* Family history of similar condition
* History of any chronic illness or hormonal abnormalities such as hirsutism, PCO…..
* History of hair loss including: age of onset, course, duration, affected site and any previous treatment taken by the patient and its response.
2. Hair examination will include:
* Pattern of hair loss (Ludwig, Olsen or Norwood)
* Pull test
* Scalp skin condition
* Grading according to Sinclair scale
3. Evaluating tools:
* Gross photos will be taken under adequate illumination, identical settings, lighting, and position before starting treatment and at monthly follow up visits.
* Trichoscopic examination: All cases will be viewed trichoscopically from frontal, temporal, and occipital views (before treatment and at follow up visits) and will be evaluated by two blinded investigators. Establishing the diagnosis of FPHL will be done according to diagnostic criteria of FPHL. Hair density, hair diameter and peripilar sign will be recorded before and after treatment.
* Subject assessment: A 7-point scale will be used Investigations:-
* Serum vit.D will be measured for all participants • Other investigations will be done if needed according to primary patient evaluation: CBC, serum ferritin, serum calcium level, serum creatinine, hormonal (TSH, FSH, LH, prolactin, testosterone).
Therapeutic interventions:- 45 patients diagnosed as FPHL with decreased serum vitamin D will be randomly divided into 3 treatment groups:
* Group 1 (15 patients) will apply topical 5% minoxidil solution in a dose of 1ml twice daily.
* Group 2 (15 patients) will apply topical vit. D analogue (calcipotriol ointment 0.005%) twice daily (1 fingertip unit for every 2% of body surface area)
* Group 3 (15 patients) ( placebo group).
* Any side effects will be registered such as itching, scalling, burning sensation, dryness….
* Duration of treatment will continue for 3 months
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group minoxidil (Treatment group)
Topical application of Minoxidil 5% solution
Topical minoxidil
Therapeutic intervention
Group calcipotriol (Treatment group)
Topical application of vitamin D3 analogue (Calcipotriol ointment)
Topical Vitamin D
Therapeutic intervention
Group 3 (Negative control group)
This group will be given saline
Saline spray
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topical minoxidil
Therapeutic intervention
Topical Vitamin D
Therapeutic intervention
Saline spray
placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with normal serum vit.D level
* Oral or parentral vitamin D supplementation for the last 3 months
* Treatment with topical vitamin D analogs in the past month
* Patients who received hair tonics or any specific hair therapy over the last 3 months prior to enrollement in the study.
* Patients with diabetes mellitus, renal disease, thyroid and parathyroid abnormalities, or autoimmune diseases.
* Patients who are pregnant, lactating or on contraceptive pills.
15 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doaa Gaber Abdel baset
Assistant Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Essam A Nada, MD
Role: STUDY_CHAIR
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Facult of Medicine, Sohag Uniiversity
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-23-07-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.